Previous 10 | Next 10 |
home / stock / ngenf / ngenf news
Phase 1b/2a trial of NervGen’s lead compound, NVG-291, is based upon unprecedented, peer-reviewed animal studies demonstrating pronounced functional recovery from spinal cord injury “The ability of NVG-291 to demonstrate meaningful recovery in motor function, sen...
Department of Defense now able to Move Forward on Brain Plasticity Research Cincinnati, Ohio--(Newsfile Corp. - January 4, 2022) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF ) through its subsidiary, NervGen US Inc., ("NervGen" or the "Company"), a clinical stage biotech ...
Phase 1 program supports plan to start clinical trials in H2 2022 for NervGen's NVG-291 in spinal cord injury, multiple sclerosis and Alzheimer's disease indications Screening of healthy volunteers has already started for the trial's multiple ascending dose (MAD) portion In preclinical stu...
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its fina...
Safety Review Committee Provides Recommendation to Proceed to Multiple Ascending Dose Portion of the Trial Vancouver, British Columbia--(Newsfile Corp. - November 4, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF ) ("NervGen" or the "Company"), a clinical stage biotech company dedi...
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, today announced the formation of its Spina...
NVG-291 Demonstrated to be Well Tolerated Along with a Favorable Pharmacokinetic Profile Vancouver, British Columbia--(Newsfile Corp. - October 18, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF ) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating ...
Cincinnati, Ohio--(Newsfile Corp. - October 4, 2021) - NervGen Pharma Corp., through its subsidiary, NervGen US Inc., (TSXV: NGEN) (OTCQX: NGENF ) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds the...
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announced a par...
Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF). The full research publication can be found on our website at www.encodelp.com , or by clicking here . Encode Ideas, L.P., a healthcare focused ...
News, Short Squeeze, Breakout and More Instantly...
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to ...
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, w...
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical ...